Guselkumab meets primary endpoints in phase 3 psoriatic arthritis program
Johnson & Johnson’s Janssen Pharmaceutical said that its IL-23 p19 inhibitor TREMFYA (guselkumab) met the primary endpoints of American College
Continue readingCoverage of Global Pharma Industry News
Johnson & Johnson’s Janssen Pharmaceutical said that its IL-23 p19 inhibitor TREMFYA (guselkumab) met the primary endpoints of American College
Continue readingCNS biopharma company Sage Therapeutics is all set to commercially launch its ZULRESSO (brexanolone) injection in the US later this
Continue readingCalifornia-based neurobehavioral health company BlackThorn Therapeutics has raised $76 million through a Series B financing round to advance targeted therapeutics
Continue readingPixuvri EMA approval : French pharma company Servier has secured full approval for Pixuvri (pixantrone) from the European Commission (EC)
Continue readingIsraeli orthopedic medical device company OSSIO has launched the OSSIOfiber Bone Pin Family for maintenance of alignment and fixation of
Continue readingBoston Scientific acquisition of Vertiflex : US medical devices manufacturer Boston Scientific has agreed to acquire Vertiflex, a California-based manufacturer
Continue readingUS pharma giant Pfizer has opened Andover Clinical Manufacturing Facility (ACMF), a new 175,000sft biologics clinical manufacturing facility built with
Continue readingImricor Medical Systems has bagged a contract to install an MRI ablation center for the treatment of cardiac arrhythmias at
Continue readingSHINE Medical Technologies, a US radioisotopes manufacturer, began construction on its first medical isotope production facility in Janesville in Wisconsin.
Continue reading